Literature DB >> 15761261

Inhibition of malignant glioma cell growth by a survivin mutant retrovirus.

A Temme1, E Herzig, B Weigle, A Morgenroth, M Schmitz, A Kiessling, M A Rieger, H K Schackert, E P Rieber.   

Abstract

Glioblastoma multiforme (GBM) is a highly malignant brain tumor that is resistant to conventional radiotherapy and chemotherapy. The median survival time of patients with GBM has remained less than 2 years despite concerted efforts to improve therapy. As a new approach to treat GBM we generated retroviral particles encoding mutant survivin for transduction of glioma cells. We demonstrate here that retroviral overexpression of a nonphosphorylatable Thr-34 --> Ala mutant of survivin (survivinT34A), in the glioma cell lines U373 and H4 resulted in a marked increase in the percentage of cells bearing multiple nuclei, which was accompanied by significantly decreased cell proliferation, and in greater numbers of cells with hypodiploid DNA content. Administration of the broad caspase inhibitor z-Val-Ala-Asp(OMe)-fluoromethyl-ketone did not reduce the cell death rate. Yet increased nuclear translocation of apoptosis-inducing factor (AIF) was observed in cells transduced with survivinT34A, indicating caspase-independent cell death. Transduction of retroviral vectors encoding wild-type survivin also led to the appearance of multinuclear cells. In contrast to mutant survivin, overexpressed wild-type survivin did not increase the cell death rate and no enhanced nuclear AIF translocation was observed. We suggest that retroviral vectors delivering mutant survivinT34A might be employed for the treatment of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761261     DOI: 10.1089/hum.2005.16.209

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

1.  A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.

Authors:  Suvobroto Nandi; Ilya V Ulasov; Cleo E Rolle; Yu Han; Maciej S Lesniak
Journal:  J Gene Med       Date:  2009-11       Impact factor: 4.565

2.  RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo.

Authors:  Sandy Hendruschk; Ralf Wiedemuth; Achim Aigner; Katrin Töpfer; Marc Cartellieri; Daniel Martin; Matthias Kirsch; Chrysanthy Ikonomidou; Gabriele Schackert; Achim Temme
Journal:  Neuro Oncol       Date:  2011-07-25       Impact factor: 12.300

3.  Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.

Authors:  Marina Conde; Susanne Michen; Ralf Wiedemuth; Barbara Klink; Evelin Schröck; Gabriele Schackert; Achim Temme
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

4.  The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer.

Authors:  Masato Hori; Tomoharu Miki; Mayumi Okamoto; Futoshi Yazama; Hiroaki Konishi; Hiroshi Kaneko; Fumio Shimamoto; Takahide Ota; Achim Temme; Masaaki Tatsuka
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

5.  Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.

Authors:  Ira O Racoma; Walter Hans Meisen; Qi-En Wang; Balveen Kaur; Altaf A Wani
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

6.  Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53.

Authors:  Ralf Wiedemuth; Barbara Klink; Katrin Töpfer; Evelin Schröck; Gabriele Schackert; Masaaki Tatsuka; Achim Temme
Journal:  Mol Cancer       Date:  2014-05-09       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.